Impel NeuroPharma announced positive results from a recently completed Phase 1 proof-of-concept trial of INP104 for acute migraine headache. INP104 is a novel dihydroergotamine (DHE) product dosed via Impel's proprietary Precision Olfactory Delivery, or POD™, intranasal delivery device. This proof-of-concept trial, INP104-101, demonstrated statistically significant improvement in bioavailability (Cmax and AUC) of INP104 over a currently approved dihydroergotamine mesylate nasal spray, and that bioavailability of INP104 was comparable to D.H.E. 45 (dihydroergotamine mesylate) intravenous (IV) injection after twenty minutes of exposure. In addition to meeting the primary endpoint of bioavailability, INP104 was well tolerated. The majority of the clinical trial participants rated INP104 as a more acceptable method of delivery over the two comparators.